Lv4
800 积分 2022-06-29 加入
Residual Viral Expression in siRNA-Treated HBV-Replicating Cell and Mouse Models
12小时前
待确认
Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B
26天前
已完结
Can gene editing drive out HIV and hepatitis viruses from inside cells?
1个月前
已完结
Life of RISC: Formation, action, and degradation of RNA-induced silencing complex
2个月前
已完结
The impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced HBV-specific humoral and cellular immune responses
2个月前
已完结
Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA
3个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
5个月前
已完结
WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
5个月前
已关闭
Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial
5个月前
已完结
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells
5个月前
已完结
皖公网安备34019202002308
